Biologic Therapy

Investigators found a low incidence of SARs-CoV-2 among patients with inflammatory bowel disease who were taking biologic therapy, according to recently published data in the Journal of Gastroenterology and Hepatology.

Patients treated with biologic therapy for inflammatory diseases may not have a higher risk for developing melanoma, a systematic review and meta-analysis found.

Approximately one-third of patients who underwent either a biologic dose change or discontinuation did not undergo objective disease activity assessment or therapeutic drug monitoring before therapy was altered, according to data from Digestive Disease Week.

Treatment with Stelara was associated with superior outcomes in patients with Crohn’s disease who previously failed anti-TNF therapy, according to study results.

Patients with pediatric psoriasis who were treated with biologics did not have a greater risk for serious infection than those treated with nonbiologics or phototherapy, according to a study.

Administration of Remicade using a top-down approach was superior to step-up therapy in achieving clinical remission in children with Crohn’s disease, according to research from Digestive Disease Week.

A recent study showed that dual biologic therapy was linked to clinical and endoscopic improvements among patients with refractory Crohn’s disease. It was the top story in gastroenterology last week.

The American Gastroenterological Association published new guidelines focused on the treatment of children and adults with eosinophilic esophagitis.

Treatment with dual biologic therapy was associated with clinical and endoscopic improvements in patients with Crohn’s disease who previously failed multiple biologics, according to study results.

Risankizumab was well tolerated during a phase 3 study that found the drug had better efficacy than placebo at 16 weeks and treatment withdrawal at 2 years in patients with moderate to severe plaque psoriasis, according to a study published in JAMA Dermatology.